Genetic variants in Nogo receptor signaling pathways may be associated with early life adversity in schizophrenia susceptibility

por Andrews, Jessica L., Fernandez-Enright, Francesca
Publicado 2014

Lingo-1: a novel target in therapy for Alzheimer's disease?

por Fernandez-Enright, Francesca, Andrews, Jessica L.
Publicado 2016

In Vivo Pharmacological Evaluations of Novel Olanzapine Analogues in Rats: A Potential New Avenue for the Treatment of Schizophrenia

por Jafari, Somayeh, Huang, Xu-Feng, Andrews, Jessica L., Fernandez-Enright, Francesca
Publicado 2013

Novel olanzapine analogues presenting a reduced H(1) receptor affinity and retained 5HT(2A)/D(2) binding affinity ratio

por Jafari, Somayeh, Bouillon, Marc E, Huang, Xu-Feng, Pyne, Stephen G, Fernandez-Enright, Francesca
Publicado 2012

Molecular evidence of synaptic pathology in the CA1 region in schizophrenia

por Matosin, Natalie, Fernandez-Enright, Francesca, Lum, Jeremy S, Engel, Martin, Andrews, Jessica L, Gassen, Nils C, Wagner, Klaus V, Schmidt, Mathias V, Newell, Kelly A
Publicado 2016